戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 4 to 0.949 +/- 0.027 g/cm(2), P < 0.001 with ibandronate).
2 nd the amino bisphosphonates alendronate and ibandronate.
3  decreased osteoblast numbers in response to ibandronate.
4  results, a relatively high concentration of ibandronate (100 microM) increased caspase-3 activity an
5 e efficacy, adherence, and safety of monthly ibandronate (150 mg) with weekly alendronate (70 mg) wer
6                               Treatment with ibandronate (4 micrograms per mouse per day) significant
7 ausal women with ER+ breast cancer, adjuvant ibandronate 50 mg once daily does not improve DFS and sh
8 ed 1:1 to 5 years of ET with or without oral ibandronate 50 mg once daily for 3 years.
9  dose-dense chemotherapy regimens and 2:1 to ibandronate 50 mg per day orally for 2 years or observat
10 ne response of mice chronically treated with ibandronate, a commonly used bisphosphonate.
11                                 Furthermore, ibandronate also significantly decreased the MDA-231 tum
12 in-of-function mutants are also resistant to ibandronate, an inhibitor of an enzyme downstream of HMG
13 08, 2,015 patients were randomly assigned to ibandronate and 1,008 to observation.
14  was not significantly different between the ibandronate and control arms (HR, 0.97; 95% CI, 0.76 to
15          The investigational bisphosphonates ibandronate and zoledronic acid may offer the advantage
16 es of AMD reported with alendronate, 20 with ibandronate, and 14 with risedronate.
17 d by the Panel include oral clodronate, oral ibandronate, and intravenous zoledronic acid.
18 reported odds ratios (RORs) for alendronate, ibandronate, and risedronate were 3.82 (95% CI: 2.94-4.9
19  for treatment of osteoporosis (alendronate, ibandronate, and risedronate) and treatment/prevention o
20  after random assignment, DFS was 94% in the ibandronate arm and 91% in the control arm.
21                       Eleven patients in the ibandronate arm developed osteonecrosis of the jaw.
22 erienced GI issues, mainly dyspepsia, in the ibandronate arm than in the control arm (89 [16%] and 54
23 s were enrolled, 565 to ET with ibandronate (ibandronate arm) and 551 to ET alone (control arm).
24                                       In the ibandronate arm, 97/565 (17%) of patients stopped ibandr
25  crystal structure of hGGPPS in complex with ibandronate, clearly depicting the involvement of three
26                 Adjuvant treatment with oral ibandronate did not improve outcome of patients with hig
27                                     However, ibandronate did not prevent the mice from developing hin
28 ronate arm, 97/565 (17%) of patients stopped ibandronate early because of adverse events.
29                                 In contrast, ibandronate failed to inhibit MDA-231 tumor formation wi
30 n increase in disease-free survival (DFS) by ibandronate from 75% to 79.5% by using a two-sided alpha
31             Thirty-three patients, 14 in the ibandronate group and 19 in the alendronate group, compl
32 1,116 patients were enrolled, 565 to ET with ibandronate (ibandronate arm) and 551 to ET alone (contr
33 a combination therapy of low dose parenteral ibandronate (IBN) and calcitriol on top of calcium and v
34 oth regimens, weekly alendronate and monthly ibandronate, improve bone mass and are comparable in saf
35 ned the effects of the potent bisphosphonate ibandronate in a murine model of human myeloma bone dise
36               TEAM-IIB investigates adjuvant ibandronate in postmenopausal women with estrogen recept
37 s, suggesting an involvement of caspase-3 in ibandronate-induced apoptosis.
38 , z-Val-Ala-Asp-fluoromethyl ketone, blocked ibandronate-induced DNA fragmentation in MDA-231 cells,
39                                              Ibandronate is an orally and intravenously available ami
40  nitrogen-containing bisphosphonates such as ibandronate is unclear in this setting.
41       These data suggest that the effects of ibandronate on apoptosis in MDA-231 breast cancer cells
42       Here we examined the effects of the BP ibandronate on MDA-231 human breast cancer cells in bone
43           There was no significant effect of ibandronate on total myeloma cell burden, as assessed by
44  been inhibited by concurrent treatment with ibandronate or osteoprotegerin.
45 e either been recently released (intravenous ibandronate), or have completed (zoledronic acid) or are
46 e either been recently released (intravenous ibandronate), or have completed (zoledronic acid) or are
47         Adherence to therapy was higher with ibandronate (P = 0.009).
48 oma and breast and prostate cancer patients (ibandronate, pamidronate, and zoledronic acid).
49 istomorphometrical examination revealed that ibandronate reduced osteoclastic bone resorption, with i
50                               Interestingly, ibandronate reduced the numbers of megakaryocytes, a kno
51 dence suggests that alendronate, etidronate, ibandronate, risedronate, zoledronic acid, estrogen, par
52 cancer cells are restricted in bone in which ibandronate selectively deposits.
53                Patients randomly assigned to ibandronate showed no superior DFS or overall survival (
54                              However, there, ibandronate shunted the homing of bone marrow plasma cel
55  treatment with the bisphosphonate compound, ibandronate, significantly delayed the progression of os
56 ers were then observed in the spleens of the ibandronate-treated mice.
57                         In both models, BiP (ibandronate) treatment resulted in time-dependent change
58 also responded normally to immunization when ibandronate was applied to naive mice.
59                                         When ibandronate was injected into mice after a primary immun
60                DFS was numerically longer if ibandronate was used in patients younger than 40 years o
61                                              Ibandronate, which was administered (s.c. daily; 4 micro
62     We report here the efficacy analysis for ibandronate, which was released by the independent data